Clinical trials sponsored by Swiss Cancer Institute

Phase breakdown

Conditions studied

Recruiting trials led by Swiss Cancer Institute

• Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  NCT06401980 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 13 locations
• Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
  NCT07149649 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
  NCT06452394 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
  NCT07158489 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
  NCT07617610 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
  NCT07365423 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 11 locations

Common questions

How many trials is Swiss Cancer Institute recruiting for?

Swiss Cancer Institute is the lead sponsor of 6 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.